Pai.ACT: a deep-learning-powered, smartphone-delivered, acceptance and commitment therapy for parents of children with special needs: a feasibility study
NCT ID NCT06086951
First seen Sep 10, 2026 ยท Last updated Sep 10, 2026
Summary
Limited psychological support for parents of children with special needs in Hong Kong can profoundly impact the child rehabilitation process and the well-being of parent-child dyads. Leveraging previous evidence from our team's research, we have developed Pai.ACT, the first deep learning-based mental health advisory system for parents. Pai.ACT incorporates the counselling logic of Acceptance and Commitment Therapy (ACT) through natural language processing, enabling parents to engage in human-like voice-to-text conversations and receive assessments and stepped-care mental health interventions, including guided self-help materials and real-time, individual-based counselling based on ACT. Following the research and development phases, we aim to kick off the utilisation of Pai.ACT by (1) pilot-testing its feasibility, acceptability, and potential efficacy in improving mental health outcomes for parents of children with special needs and (2) researching to determine the most optimal service model for parents by exploring their perceptions through focus group interviews. Pai.ACT offers accessible and comprehensive mental health services to all Chinese-speaking parents, addressing their psychological burden in caring for children with special needs. Pai.ACT could bring substantial and enduring societal benefits to Chinese-speaking families by integrating mental health support services for family caregivers with current child rehabilitation services and non-governmental organisations. Furthermore, this could contribute to reducing the public stigma attached to special needs children while increasing mental health awareness.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
60 people
The number who actually took part.
- Started
-
Oct 2023
- Finished
-
May 2025
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
19 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Primary caregivers who are Cantonese-speaking Hong Kong residents. * The caregiver must cohabitate with the child with special needs. * The child under the participant's care should be aged between 2-8 years. The child should be either diagnosed or suspected to have one of the developmental conditions such as ASD, ADHD, or DD. These conditions must be recognised by the Child Assessment Service of the Department of Health and conform to the DSM-5 criteria. The diagnosis or suspected diagnosis should be documented in the electronic medical record at the study hospital or the case profile record at the collaborating non-governmental organisations. Note: The age range of 2-8 years was selected due to the substantial impact of parenting on the developmental milestones of preschoolers and junior school-aged children. Exclusion Criteria: * Parents diagnosed with severe mental illnesses are excluded. * Parents who are currently pregnant are excluded. * Parents who are less than six months postpartum are excluded. * Parents with a developmental disability that interferes with their ability to comprehend the program's content are excluded. * Parents with cognitive, language, communication, visual, or hearing impairments or disorders that could impede their understanding of the intervention content are excluded. * Parents currently participating in other psychosocial, psychoeducational, or parenting interventions are excluded.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Attention deficit hyperactivity disorder are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The Chinese University of Hong Kong
Hong Kong, Hong Kong
-
The Pamela Youde Nethersole Eastern Hospital
Hong Kong, Hong Kong
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Effectiveness of the B.A.S.I.C.S. framework as a multimodal Play-Based intervention for children with autism spectrum disorder: a retrospective cohort study
- Heart rate variability biofeedback for anxiety in autistic youth
- Artificial intelligence-driven, chatbot-assisted acceptance and commitment therapy (Pai.ACT) for parents of young children with neurodevelopmental disorders: a randomised controlled trial
- A phase II/III Double-Blind, randomised and Controlled-to-Open-Label study assessing the efficacy of Full-Spectrum medicinal cannabis plant extract 0.08% THC (NTI164) on the severity of autism spectrum disorder in young people
- Can a tiny dose of cannabis ease autism symptoms in children?
- A Baby's fidgets may reveal brain health: study tests early warning signs